A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS

Trial Profile

A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Neurotrophic factor producing mesenchymal stem cell therapy BrainStorm Cell therapeutics (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Sponsors Brainstorm Cell Therapeutics
  • Most Recent Events

    • 07 Feb 2018 According to a Brainstorm Cell therapeutics media release, two scientific posters from this phase 2 study study will be presented as platform presentations at the American Academy of Neurology (AAN) Annual Meeting.
    • 29 Nov 2017 According to a Brainstorm Cell therapeutics media release, data from this trial will be presented at the 28th International Symposium on ALS/MND 2017.
    • 01 May 2017 According to a Brainstorm Cell therapeutics media release, data from this trial will be presented at International Society for Cellular Therapy Annual Conference (ISCT) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top